Literature DB >> 16513683

Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsy.

Pierre Thomas1, Luc Valton, Pierre Genton.   

Abstract

Aggravation of idiopathic generalized epilepsy (IGE) syndromes by inappropriate antiepileptic drugs (AEDs) is increasingly recognized as a serious and common problem. Precipitation of status epilepticus (SE) by inappropriate medication has rarely been reported. We retrospectively studied all adult patients with IGE taking at least one potentially aggravating AED, who developed video-EEG documented SE over 8 years, and whose long-term outcome was favourable after adjustment of medication. We identified 14 patients (seven male patients) aged 15-46 years with a mean duration of epilepsy of 16.4 years. Video-EEG demonstrated typical absence SE (ASE) in five, atypical ASE in five, atypical myoclonic SE (MSE) in three and typical MSE in one. Epilepsy had been misclassified as cryptogenic partial in eight cases and cryptogenic generalized in four. The correct diagnosis proved to be juvenile absence epilepsy (JAE) in six patients, juvenile myoclonic epilepsy (JME) in four, epilepsy with grand mal on awakening (EGMA) in two and childhood absence epilepsy (CAE) in two. All patients had been treated with carbamazepine (CBZ) and had experienced seizure aggravation or new seizure types before referral. Seven patients had polytherapy with phenytoin (PHT), vigabatrin (VGB) or gabapentin (GBP). Potential precipitating factors included dose increase of CBZ or of CBZ and PHT; initiation of CBZ, VGB or GBP; and decrease of phenobarbital. Withdrawal of the aggravating agents and adjustment of medication resulted in full seizure control. This series shows that severe pharmacodynamic aggravation of seizures in IGE may result in ASE or MSE, often with atypical features.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16513683     DOI: 10.1093/brain/awl047

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  28 in total

1.  Potentiation of mGlu5 receptors with the novel enhancer, VU0360172, reduces spontaneous absence seizures in WAG/Rij rats.

Authors:  V D'Amore; I Santolini; C M van Rijn; F Biagioni; G Molinaro; A Prete; P J Conn; C W Lindsley; Y Zhou; P N Vinson; A L Rodriguez; C K Jones; S R Stauffer; F Nicoletti; G van Luijtelaar; R T Ngomba
Journal:  Neuropharmacology       Date:  2012-06-15       Impact factor: 5.250

Review 2.  Pharmacotherapy for Focal Seizures in Children and Adolescents.

Authors:  Clare E Stevens; Carl E Stafstrom
Journal:  Drugs       Date:  2018-09       Impact factor: 9.546

Review 3.  The safety and tolerability of newer antiepileptic drugs in children and adolescents.

Authors:  Dean P Sarco; Blaise F D Bourgeois
Journal:  CNS Drugs       Date:  2010-05       Impact factor: 5.749

Review 4.  Genetic generalized epilepsies in adults - challenging assumptions and dogmas.

Authors:  Bernd J Vorderwülbecke; Britta Wandschneider; Yvonne Weber; Martin Holtkamp
Journal:  Nat Rev Neurol       Date:  2021-11-26       Impact factor: 42.937

Review 5.  CNS adverse events associated with antiepileptic drugs.

Authors:  Gina M Kennedy; Samden D Lhatoo
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 6.  Epilepsy and cognitive impairments in Alzheimer disease.

Authors:  Jorge J Palop; Lennart Mucke
Journal:  Arch Neurol       Date:  2009-02-09

7.  Neurochemical and behavioral features in genetic absence epilepsy and in acutely induced absence seizures.

Authors:  A S Bazyan; G van Luijtelaar
Journal:  ISRN Neurol       Date:  2013-05-07

8.  Use of the newer antiepileptic drugs in pediatric epilepsies.

Authors:  Amy D Malphrus; Angus A Wilfong
Journal:  Curr Treat Options Neurol       Date:  2007-07       Impact factor: 3.598

9.  Treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy.

Authors:  Stéphane Auvin
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570

10.  The adolescent or adult with generalized tonic-clonic seizures.

Authors:  Roop Gursahani; Namit Gupta
Journal:  Ann Indian Acad Neurol       Date:  2012-04       Impact factor: 1.383

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.